Allogene Therapeutics, Inc. financial data

Symbol
ALLO on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
210 East Grand Avenue, South San Francisco, CA
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2024 - Nov 7, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.17K % +21.1%
Debt-to-equity 26.3 % +8.24%
Return On Equity -58.1 % -5.47%
Return On Assets -46 % -3.79%
Operating Margin -693K % -104%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 210M shares +24.6%
Common Stock, Shares, Outstanding 210M shares +24.6%
Entity Public Float 557M USD -44.8%
Common Stock, Value, Issued 210K USD +25%
Weighted Average Number of Shares Outstanding, Basic 209M shares +24.8%
Weighted Average Number of Shares Outstanding, Diluted 209M shares +24.8%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 43K USD -57%
Research and Development Expense 202M USD -23.4%
General and Administrative Expense 66.9M USD -11.3%
Operating Income (Loss) -298M USD +12.2%
Nonoperating Income (Expense) 14.4M USD +5413%
Net Income (Loss) Attributable to Parent -283M USD +16.3%
Earnings Per Share, Basic -1.54 USD/shares +32.2%
Earnings Per Share, Diluted -1.54 USD/shares +32.2%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 51.2M USD -26%
Cash, Cash Equivalents, and Short-term Investments 403M USD -18.9%
Assets, Current 304M USD -35.7%
Property, Plant and Equipment, Net 89M USD -13.5%
Operating Lease, Right-of-Use Asset 46.3M USD -41.1%
Other Assets, Noncurrent 4.97M USD -48.1%
Assets 589M USD -17.4%
Accounts Payable, Current 5.51M USD -11.3%
Employee-related Liabilities, Current 12.7M USD -29.4%
Contract with Customer, Liability, Current 86K USD 0%
Liabilities, Current 32.6M USD -13.1%
Operating Lease, Liability, Noncurrent 85.1M USD -5.51%
Other Liabilities, Noncurrent 7.67M USD +47.8%
Liabilities 125M USD -5.58%
Accumulated Other Comprehensive Income (Loss), Net of Tax 157K USD
Retained Earnings (Accumulated Deficit) -1.76B USD -19.2%
Stockholders' Equity Attributable to Parent 464M USD -20.1%
Liabilities and Equity 589M USD -17.4%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -55.9M USD +16.1%
Net Cash Provided by (Used in) Financing Activities 1.65M USD -4.68%
Net Cash Provided by (Used in) Investing Activities 22.1M USD -80.4%
Common Stock, Shares Authorized 400M shares 0%
Common Stock, Shares, Issued 210M shares +24.6%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -32.1M USD -167%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 61.5M USD -22.6%
Deferred Tax Assets, Valuation Allowance 400M USD +25%
Deferred Tax Assets, Gross 418M USD +21.7%
Operating Lease, Liability 92.5M USD -4.3%
Depreciation 3.56M USD +1.37%
Payments to Acquire Property, Plant, and Equipment 1.04M USD -45.6%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -281M USD +14.4%
Lessee, Operating Lease, Liability, to be Paid 122M USD -6.9%
Property, Plant and Equipment, Gross 149M USD -1.25%
Operating Lease, Liability, Current 7.39M USD +12.3%
Lessee, Operating Lease, Liability, to be Paid, Year Two 13.2M USD +4.25%
Lessee, Operating Lease, Liability, to be Paid, Year One 12.9M USD +3.8%
Operating Lease, Weighted Average Discount Rate, Percent 0.06 pure -14.5%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 29.8M USD -14.1%
Lessee, Operating Lease, Liability, to be Paid, Year Three 13.6M USD +6.19%
Deferred Tax Assets, Operating Loss Carryforwards 211M USD +21.2%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 18.9M USD +29.7%
Lessee, Operating Lease, Liability, to be Paid, Year Four 14.1M USD +6.18%
Operating Lease, Payments 3.1M USD +3.33%
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense 13.4M USD -13%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%